A5073968518- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Venous Thromboembolism Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Lymphoma Diagnosis and Treatment
- Atrial Fibrillation Management and Outcomes
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- COVID-19 and healthcare impacts
- Chronic Lymphocytic Leukemia Research
- Sexual function and dysfunction studies
- Cutaneous lymphoproliferative disorders research
- SARS-CoV-2 and COVID-19 Research
- Uterine Myomas and Treatments
- Diabetes and associated disorders
Royal Hallamshire Hospital
2017-2025
Sheffield Teaching Hospitals NHS Foundation Trust
2021-2024
Abstract Brexucabtagene autoleucel (brexu‐cel) is an autologous CD19 CAR T‐cell product, approved for relapsed/refractory (r/r) mantle cell lymphoma (MCL). In ZUMA‐2, brexu‐cel demonstrated impressive responses in patients failing ≥2 lines, including a bruton's tyrosine kinase inhibitor, with overall and complete response rate of 93% 67%, respectively. Here, we report our real‐world intention‐to‐treat (ITT) outcomes consecutive, prospectively patients, from 12 institutions the United Kingdom...
ABSTRACT Introduction Heavy menstrual bleeding (HMB) is a common presenting symptom in women with disorders, yet haemostatic testing sometimes overlooked, even when refractory HMB requires surgical intervention. Aim To determine the prevalence of disorders referred for management and investigate screening approaches this population. Methods Women were enrolled prospectively underwent detailed investigation. The International Society on Thrombosis Haemostasis Bleeding Assessment Tool...
Summary Coagulation dysfunction and thrombosis are major complications in patients with coronavirus disease 2019 (COVID‐19). Patients on oral anticoagulants (OAC) prior to diagnosis of COVID‐19 may therefore have better outcomes. In this multicentre observational study 5 883 (≥18 years) admitted 26 UK hospitals between 1 April 2020 31 July 2020, overall mortality was 29·2%. Incidences thrombosis, bleeding (MB) multiorgan failure (MOF) were 5·4%, 1·7% 3·3% respectively. The presence MB, or...
Coagulation dysfunction and thrombosis are major complications in patients with coronavirus disease-19 (COVID-19). Patients on oral anticoagulants prior to diagnosis of COVID-19 may therefore have better outcomes. We aimed:To first document the frequency thrombosis, bleeding multiorgan failure (MOF) admitted contribution these 90-day mortality.To then determine effects anticoagulation, use admission same outcomes as well requirement for Intensive Care Unit (ICU) admission, when compared a...